Welcome to the Cannabis Countdown. In this week’s rendition, we’ll recap and countdown the top 10 Marijuana and Psychedelic Stock News stories for the week of March 23rd – 29th, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view full article.
10. These 2 Companies are Turning LSD, Magic Mushrooms, Ketamine and MDMA into the Next Blockbuster Drugs
Early Weed Investors and Business Minds are Positioning Themselves in the World of Psychedelic Medicine as the Flow of Smart Money Hits the Market
Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1) founder Bruce Linton and Billionaire “Mr. Wonderful” Kevin O’Leary from Shark Tank, are going all-in on what they think is a much bigger opportunity than the Cannabis Boom. Investors who missed the last bull market in Weed Stocks or got in too late should start researching the “Shroom Boom” immediately.
READ FULL PSYCHEDELIC STOCKS ARTICLE
9. Panic Buying Shifts from Toilet Paper to Pot Stocks Amid COVID-19 Crisis, 8 Weed Stocks Jump Over 150%
Pot Stocks Are Skyrocketing During Coronavirus Demand Spike as Cannabis Industry Deemed ‘Essential’
Since reaching new lows during the stock market’s massive Coronavirus correction, most Pot Stocks have reversed sharply and are now soaring at a time no one could have predicted. These 8 Cannabis Stocks have recently soared more than 150%, with 4 posting gains of over 200%.
READ FULL PANIC BUYING ARTICLE
8. Cannabis Stocks Extend Rally as Pot Sector Awakens, Curaleaf Reports Strong Earnings
Curaleaf Reported Record Revenue with Full-Year 2019 Sales Climbing 187% Over the Previous Year
For the second day in a row, U.S. multi-state operators (MSOs) like Curaleaf (CSE: CURA) (OTCQX: CURLF), which reported earnings today, led the way as the cannabis sector continued its strong performance compared to the broad market.
READ FULL POT STOCKS + CURALEAF ARTICLE
7. Curaleaf is Worth $22 Per Share, Beacon Says
Beacon Securities Analyst Russell Stanley is Keeping the Faith With U.S. Cannabis Stock Curaleaf
In an update to clients on Wednesday, Stanley reiterated his “Buy” rating and CDN $22 target price on Curaleaf (CSE: CURA) (OTCQX: CURLF), saying that so far the company’s operations haven’t been disrupted by COVID-19.
6. MindMed Advances 18-MC, Potential Treatment for Opioid Addiction, Into Further Clinical Testing
Mind Medicine (MindMed) Continues Research, Without Interruption, and on Schedule
Psychedelics firm MindMed (NEO: MMED) (OTC: MMEDF) (FRA: BGHM) announced that the company has begun enrollment in further human safety studies of 18-MC, the company’s orally-active drug candidate for the treatment of opioid use disorders.
5. Why Tilray Stock Is Soaring Again After a Terrible Year
Something is Moving Tilray’s Stock Far Higher Than Other Pot Stocks
A month ago, shares of Canadian licensed producer (LP) Tilray (NASDAQ: TLRY) (FRA: 2HQ) closed at $16.57. On March 25, shares closed at $5.04. In the early afternoon on March 26, the stock traded at around $8.39, up about 67% for the day.
4. Why Green Thumb Industries’ Marijuana Sales Soared in Q4
But the News Wasn’t as Great for the U.S. Cannabis Operator’s Bottom Line
Green Thumb Industries (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2) announced its 2019 fourth-quarter and full-year Earnings after the market closed on Thursday. Was there news that could help accelerate the stock’s comeback? Here are the highlights from the company’s Q4 update.
READ FULL GTII EARNINGS ARTICLE
3. Champignon Brands Bull Pennant Technical Breakout, Continuation of Uptrend Highly Likely
Bull Pennants Are Continuation Patterns, Indicating SHRM’s Current Uptrend is Highly Likely to Continue
Psychedelics stock Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FRA: 496) soared 15% on Wednesday officially breaking out of its bullish chart formation. Following Friday’s very strong close, the probability of SHRM’s uptrend continuing has been increased substantially. Champignon Brands is a leading psychedelics and health and wellness company focused on creating the most compelling IP portfolio, clinical pipeline and drug development platform in the psychedelics space.
READ FULL SHRM BREAKOUT ARTICLE
2. 5 Pot Stocks That Can Survive the Coronavirus Crash
These Marijuana Stocks Have the Tools to Outlast the COVID-19 Pandemic
These 5 Pot Stocks look as if they’ll have little to no trouble surviving this Coronavirus crash. As the marijuana industry washes out, look for these Marijuana Stocks to step forward as leaders.
READ FULL MARIJUANA STOCKS ARTICLE
1. These Pot Stocks Soared Today as Demand for Cannabis Spikes Amid COVID-19 Pandemic
The Coronavirus Outbreak Has Forced Many to Self-Quarantine, Resulting in Surging Demand for Cannabis
As financial markets fell again, these Cannabis Stocks soared in reaction to the COVID-19 related spike in demand for pot products.
Follow The Cannabis Investor on Social Media: Facebook | Instagram | Twitter | LinkedIn | Investor Group
Follow Psychedelic Profits on Social Media: Facebook | Instagram | Twitter | LinkedIn | Investor Group
Did you enjoy this article? If so, sign up for our Email Newsletter below to start receiving our weekly recap of the week’s best articles.
Also Read: These 2 Companies are Turning LSD, Magic Mushrooms, Ketamine and MDMA into the Next Blockbuster Drugs
The Most Anticipated U.S. MSO IPO of 2020 is Drawing Near
The Cannabis Sector is Long Overdue for a High-Profile IPO
The Wait is Nearly Over, TCI’s MSO IPO of 2020 is Almost Here
Get Your Copy of The Ultimate Cannabis Investing Guide
Join the Discussion in the TCI Investor Group
Featured ArticlesCannabis Stock NewsCannabis Industry ArticlesTechnical Analysis ArticlesWatch Cannabis Stock Videos